Lemaitre Vascular Inc.

(Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

) Quarterly Dividend On April 28, 2026, the Company s Board of Directors approved a quarterly dividend of $0.25/share of common stock.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

The dividend will be paid on June 4, 2026, to stockholders of record on May 21, 2026.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Share Repurchase Program On February 19, 2026, the Company s Board of Directors authorized the repurchase of up to $100.0mm of the Company s common stock.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Recently Adopted Accounting Pronouncements In November 2024, the FASB issued ASU 2024-04, Induced Conversions of Convertible Debt Instruments.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

Chairman/CEO George LeMaitre said, Higher ASPs, geographic expansion and disciplined spending produced 11% sales growth and 42% EPS growth in Q1.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

In addition to total segment net income, the CODM s quarterly reporting package includes several highlighted expense categories that the CODM considers key strategic drivers of the Company s long-term profitability.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

We have grown our business using a three-pronged strategy: 1) pursuing a focused call point, 2) competing for sales of low-rivalry, niche products, and 3) expanding our worldwide direct sales force while acquiring complementary devices.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

Statements in this press release regarding the Company s business that are not historical facts may be forward-looking statements that involve risks and uncertainties.

SEC original ↗Lemaitre Vascular Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Legal Proceedings 29 Item 1A.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

The estimation of self insurance liabilities is a significant accounting estimate because it requires judgment and is subject to inherent uncertainty.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.

SEC original ↗Lemaitre Vascular Inc. — 10-Q Quarterly report10-QAug 5, 2026